Compliance · State rules

Office-use compounding in Massachusetts

Not prohibited — redefined: doing it makes the supplier an outsourcing facility by statute

USPeptideRx EditorialLast reviewed: August 30, 2026

Massachusetts answers this question with a definition rather than a prohibition, and it is the only state reviewed here that does. It does not say a pharmacy may not supply office stock. It says that compounding and distributing sterile preparations in volumes inconsistent with normal patient-specific prescribing, or without accountability documentation, IS operating as an outsourcing facility — and that an entity doing that must meet federal manufacturing-quality standards and register with the FDA. The practical answer for a prescriber is the same as a prohibition on the 503A side, but the mechanism matters: the question is which kind of facility may supply you, not whether anyone may. This is the state where the 2012 meningitis outbreak happened, and this is the answer it wrote afterwards.

The governing rule

Massachusetts’s office-use position is set by M.G.L. c. 112 § 36E (definition and registration); § 39F (the consequence); § 39D (defined terms). The text below is quoted verbatim; everything outside a quote block is our summary of it, and the two are kept visually separate on purpose.

M.G.L. c. 112 § 36E(a) — the definition that decides it

"Operate as an outsourcing facility", compound and distribute a sterile drug preparation within or outside of the commonwealth: (i) in volumes inconsistent with routinely observed volume patterns associated with patient-specific prescriptions; or (ii) in the absence of accountability documentation.

M.G.L. c. 112 § 39F(c) — what follows from meeting that definition

An entity that intends to compound and distribute a sterile drug preparation or a complex nonsterile drug within or outside of the commonwealth in volumes inconsistent with routinely observed volume patterns associated with patient-specific prescriptions or in the absence of accountability documentation shall adhere to the most current standards established under cGMP when engaging in any form of compounding.

M.G.L. c. 112 § 39F(c), continued — and the registration it compels

The entities shall either register as a producer of drugs with the federal Food and Drug Administration pursuant to section 510 of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. section 360 or register as an outsourcing facility with both the federal Food and Drug Administration pursuant to section 503B of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. § 353b, and the board of registration in pharmacy pursuant to section 36E before engaging in any sterile compounding or complex nonsterile compounding.

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

The mechanism, and why the wording of the verdict mattersHigh confidence: No Massachusetts provision says office use is forbidden. The statute defines the conduct as operating as an outsourcing facility, and then attaches consequences to that status: current good manufacturing practice standards, and registration with the FDA under either the drug-producer section or the outsourcing-facility section. A pharmacy that supplies office stock has not broken a compounding rule so much as become a different kind of regulated entity without the credential for it.
The trigger is a comparison to your own prescribing history, not a numberHigh confidence: The threshold is volumes "inconsistent with routinely observed volume patterns associated with patient-specific prescriptions". There is no percentage and no unit count. The benchmark is the pharmacy’s own patient-specific prescription pattern, which means the same volume can sit inside the definition at one pharmacy and outside it at another. The second limb needs no volume at all: an absence of accountability documentation is independently sufficient.That is a genuinely unusual drafting choice and it cuts both ways. There is no bright line to stay under, and equally none for a regulator to point at — the question is evidential rather than arithmetic.
The state routes you into the federal registration itselfHigh confidence: Most states in this file that mention federal law require compliance with it. Massachusetts goes further and makes the federal registration the state-law consequence of the conduct, naming both section 510 and section 503B. It then requires registration with the Massachusetts board as well, so the entity ends up holding both. State permission and the federal exemption remain independent questions — 21 U.S.C. § 353a still conditions the federal exemptions on a patient-specific prescription.
Sterile and complex non-sterile are both reached, but not identicallyHigh confidence: The definition in § 36E is written about a sterile drug preparation. The consequence in § 39F reaches "a sterile drug preparation or a complex nonsterile drug", so the cGMP-and-registration duty covers more ground than the definition that triggers it. Section 39F separately requires a board licence for sterile compounding and for complex non-sterile compounding, under different sections.
Last changeHigh confidence: Massachusetts rebuilt this area of law wholesale in 2014, after the 2012 contamination outbreak that originated in a Massachusetts compounding pharmacy. The board’s regulations now carry four separate compounding licence categories, and the outsourcing facility registration sits in its own chapter at 247 CMR 21.00.

Massachusetts at a glance

Massachusetts office-use compounding summary, reviewed 2026-08-30
Human office use	Not prohibited — the conduct is defined as operating as an outsourcing facility
Sterile preparations	The trigger names sterile; the duty reaches sterile and complex non-sterile
Quantity cap	No number — measured against the pharmacy’s own prescription patterns
Mandatory label legend	Not established for this page — see the scope note
Board reporting	Accountability documentation; its absence is independently a trigger
Last change	Statutory framework rebuilt in 2014
Governing rule	M.G.L. c. 112 § 36E (definition and registration); § 39F (the consequence); § 39D (defined terms)

Receiving 503B office stock in Massachusetts

Massachusetts uses the literal term for the credential, so searching its law for "outsourcing facility" works. Beyond that, this section is deliberately short: the research that produced this page established the supply side from primary text and did not establish the receiving side, and the honest thing to publish is the boundary rather than an estimate.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What Massachusetts asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inMedium confidence: A registration from the Board of Registration in Pharmacy, which sits inside the Department of Public Health. The board’s own chapter for it is 247 CMR 21.00, which carries separate resident, provisional and non-resident regimes, and the statutory authority is the same § 36E that supplies the definition above.The fee, whether it is charged per location, and the mechanics of the non-resident route were not established for this page and are not stated here.
Does your practice need a permit?Low confidence: Not established. We did not determine whether a Massachusetts practice holding compounded stock needs its own credential, and we are not going to guess at it for the largest market in this region. Ask the board before relying on an answer.
Administer vs dispenseLow confidence: Not established for Massachusetts specifically. What is established is the supply-side mechanism above, which turns on the volume and documentation of what a pharmacy distributes rather than on what the receiving practice then does with it.
Scheduled (controlled) stockLow confidence: A Massachusetts Controlled Substances Registration exists, under M.G.L. c. 94C and the board’s regulations at 247 CMR 11.00. Which unit issues it, whether it is required per location, and how it sequences with the federal registration were not established for this page.

How to check a facility’s credential before you order is set out in how to place an office-use order.

The federal layer still applies

Whatever Massachusetts law allows, federal law applies on top of it and is not satisfied by state permission. 21 U.S.C. § 353a conditions the federal compounding exemptions on a drug being compounded for an identified individual patient on receipt of a valid prescription order. A state rule cannot create a federal safe harbour, and several state rules say so in their own text. The separate federal pathway for non-patient-specific office stock is the 503B outsourcing facility — the differences are set out in 503A vs 503B.

For how Massachusetts compares with the other states reviewed, see the state-by-state comparison.

What this page does not establish

This page publishes Massachusetts’s supply-side answer and deliberately stops short of its receiving-side detail. The supply-side finding — the reclassification mechanism — was read in full from the Legislature’s own text and is stated with confidence. The receiving side was not researched to the same depth, so the fee for an outsourcing facility registration, whether it is charged per location, whether a receiving practice needs its own permit, whether the qualifying party is the person or the entity, and the mechanics of the state controlled-substances registration are all absent here rather than estimated. Massachusetts is the largest market in this region and it deserves a better answer than an inference; treat this section as a placeholder and ask the board.
Whether Massachusetts has a percentage-based wholesale exemption of the kind several other states use was not checked, and nothing on this page should be read as saying it does or does not.
Board minutes from late 2025 and early 2026 discuss office use and office stock and have not been analysed for this page. They are the most likely place for a regulator position that would sharpen what is written above.
We searched no case law, attorney-general opinions or disciplinary orders for this state, and search engines were unavailable when it was researched. Read nothing into that silence — it means we have not looked, not that nothing is there.

Sources

Primary sources, fetched directly from the issuing body. No secondary summaries.